Carl Goldfischer

MD

Carl S. Goldfischer, MD has spent over 30 years in the biotechnology industry as an executive, investor and member of boards of directors. From 2000 until 2022 he was a managing director, partner and member of the board of directors of Bay City Capital a leading San Franciso based health care investment firm. During that time helped oversee the firm's investment activities across several funds and a myriad of investments in the biopharmaceutical and medical device space with over $2b in deployed capital. These investments ranged from novel technologies sourced from leading academic laboratories to the restructuring of publicly listed companies. He has a board range of investment skills ranging from scientific depth of knowledge to expertise in public equity markets and deal structuring. He has been managing a family office, Teal Trace Partners and just founded SKIA capital with 4 partners. SKIA will initially focus on public biotechnology companies with novel assets that are currently trading at deep discounts to their intrinsic value but require additional capital, management expertise and board membership to reach relatively near-term value inflection milestones.